GSK’s Emma Walmsley Made A Dame In UK Honors
Knighthood for Synairgen’s Stephen Holgate
Executive Summary
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.
You may also be interested in...
Synairgen Supercharges R&D With $100m Financing
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.